259 related articles for article (PubMed ID: 22607010)
1. Oxybutynin gel for the treatment of overactive bladder.
Gomelsky A; Dmochowski RR
Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
[TBL] [Abstract][Full Text] [Related]
2. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
Sahai A; Mallina R; Dowson C; Larner T; Khan MS
Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
[TBL] [Abstract][Full Text] [Related]
3. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
Staskin DR; Robinson D
Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
[TBL] [Abstract][Full Text] [Related]
4. Transdermal oxybutynin: sticking to the facts.
Cartwright R; Cardozo L
Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
[TBL] [Abstract][Full Text] [Related]
5. Transdermal oxybutynin for overactive bladder.
Davila GW; Starkman JS; Dmochowski RR
Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
Sand PK; Davila GW; Lucente VR; Thomas H; Caramelli KE; Hoel G
Am J Obstet Gynecol; 2012 Feb; 206(2):168.e1-6. PubMed ID: 21963104
[TBL] [Abstract][Full Text] [Related]
7. Oxybutynin topical and transdermal formulations: an update.
Staskin DR; Salvatore S
Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
[TBL] [Abstract][Full Text] [Related]
9. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration.
Gleason JM; Daniels C; Williams K; Varghese A; Koyle MA; Bägli DJ; Pippi Salle JL; Lorenzo AJ
J Pediatr Urol; 2014 Aug; 10(4):753-7. PubMed ID: 24477421
[TBL] [Abstract][Full Text] [Related]
10. Transdermal drug delivery treatment for overactive bladder.
Dmochowski RR; Starkman JS; Davila GW
Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
[TBL] [Abstract][Full Text] [Related]
11. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
[TBL] [Abstract][Full Text] [Related]
12. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
[TBL] [Abstract][Full Text] [Related]
13. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
Cartwright R; Srikrishna S; Cardozo L; Robinson D
BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
[TBL] [Abstract][Full Text] [Related]
17. In brief: Oxytrol OTC.
Med Lett Drugs Ther; 2013 Sep; 55(1425):76. PubMed ID: 24662958
[No Abstract] [Full Text] [Related]
18. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
Ho C
Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
[TBL] [Abstract][Full Text] [Related]
19. The evolution of transdermal therapy for overactive bladder.
Sand PK
Curr Urol Rep; 2009 Sep; 10(5):338-41. PubMed ID: 19709479
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]